ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2020
Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 16 citations in OpenAlex.
- Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts.bioRxiv : the preprint server for biology · 2026Article
- Resolving Heterogeneity in the Diagnosis of Alzheimer's Disease and its Progression Using Multimodal Data.Journal of molecular neuroscience : MN · 2026Article
- Amyloid and tau pathologies are drivers of white matter damage in aging and Alzheimer's disease.medRxiv : the preprint server for health sciences · 2025Article
- Predicting future cognitive impairment in preclinical Alzheimer's disease using multimodal imaging: a multisite machine learning study.medRxiv : the preprint server for health sciences · 2025Article
- Effects of exercise-cognitive dual-task training on elderly patients with cognitive frailty and depression.World journal of psychiatry · 2025Article
- Applying machine learning to high-dimensional proteomics datasets for the identification of Alzheimer's disease biomarkers.Fluids and barriers of the CNS · 2025Article
- Effects of exercise-cognitive dual-task training on cognitive frailty in older adults: a randomized controlled trial.Frontiers in aging neuroscience · 2025Article
- Evaluation of ComBat Harmonization for Reducing Across-Tracer Differences in Regional Amyloid PET Analyses.Human brain mapping · 2024Article
- Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.European journal of nuclear medicine and molecular imaging · 2023Article
- Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach.Alzheimer's research & therapy · 2023Article
- The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.Alzheimer's research & therapy · 2022Article
- Subtyping of mild cognitive impairment using a deep learning model based on brain atrophy patterns.Cell reports. Medicine · 2021Article
- Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease.Alzheimer's research & therapy · 2021Article
- Early detection of amyloid load usingAlzheimer's research & therapy · 2021Article
- Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment.Alzheimer's & dementia (New York, N. Y.) · 2020Review
- Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
introductionAbnormal brain amyloid beta (Aβ) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown whether the assessment of the topographical distribution of Aβ pathology can provide additional information to identify, among global Aβ positive individuals, those destined for dementia.
methodsWe studied 260 amnestic mild cognitive impairment (MCI) subjects who were Aβ-PET positive with [
resultsNeither global nor regional [ DISCUSSION: These results highlight that the regional distribution of Aβ abnormality may provide important complementary information at an individual level regarding the likelihood of Aβ positive MCI to progress to dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.